E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
|
E.1.1.1 | Medical condition in easily understood language |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Cancer [C04] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 19.0 |
E.1.2 | Level | PT |
E.1.2 | Classification code | 10018336 |
E.1.2 | Term | Glioblastoma |
E.1.2 | System Organ Class | 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
The primary objective of this study is to investigate whether the addition of bevacizumab to lomustine improves overall survival (OS) in patients with recurrent glioblastoma compared to treatment with lomustine alone. |
|
E.2.2 | Secondary objectives of the trial |
Secondary endpoints will be:
- Progression free survival distribution according to RANO criteria (PFS: distribution, PFS 6 and PFS12)
- Response distribution, objective response rate, duration of response (according to RANO criteria), progression pattern.
- Overall survival: distribution and OS 24
- Complete safety profile according to CTCAE version 4.0.
- Patient-oriented criteria: clinical/neurological deterioration free survival, steroid use, quality of life (by patients and caregivers/relatives) and development of cognitive deterioration. |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
-Histologically confirmed de novo glioblastoma (primary) with unequivocal first progression after RT (radiotherapy) concurrent/adjuvant chemotherapy at least 3 months off the concomitant part of the chemoradiotherapy.
-Availability of biological material for central review processes and translational research projects.
-Patient may have been operated for recurrence. If operated:
*residual and measurable disease after surgery is not required but surgery must have confirmed the recurrence
*a post-surgery MRI should be available within 48 hours following surgery
*Surgery completed at least 2 weeks before registration and patients should have fully recovered
-Craniotomy or intracranial biopsy site must be adequately healed free of drainage or cellulitis, and the underlying cranioplasty must appear intact at the time of randomisation.
-Absence of any cardiovascular disorder
-Absence of known hypersensitivity:
*to any part of the bevacizumab or lomustine formulations.
*to Chinese hamster ovary cell products or other recombinant human or humanized antibody.
-Age ≥18 years
-WHO Performance status 0-2
-Women of childbearing potential (WOCBP) must be using an adequate method of contraception to avoid pregnancy throughout the study in such a manner that the risk of pregnancy is minimized. In general, the decision for appropriate methods to prevent pregnancy should be determined by discussions between the investigator and the study subject. WOCBP include any female who has experienced menarche and who has not undergone successful surgical sterilization (hysterectomy, bilateral tubal ligation, or bilateral oophorectomy) or is not postmenopausal. Females should not be breast feeding.
-Males must agree to use an effective method of contraception durign the tratment period and for at least 6 months after the last study treatment. |
|
E.4 | Principal exclusion criteria |
-More than one line of chemotherapy (concurrent and adjuvant temozolomide based chemotherapy including in combination with another investigational agent is considered one line of chemotherapy). Chemotherapy must have been completed at least 4 weeks prior to randomization.
-Current or recent (within 4 weeks before randomization) treatment with another investigational drug.
-Prior treatment with bevacizumab or other VEGF inhibitors or VEGF-Receptor signaling inhibitors.
-Radiotherapy within the three months prior to the diagnosis of progression.
-Radiotherapy with a dose over 65 Gy, stereotactic radiosurgery or brachytherapy unless the recurrence is histologically proven.
-Prior treatment with nitrosoureas. |
|
E.5 End points |
E.5.1 | Primary end point(s) |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
Treatment effect measured by the hazard ratio (HR) |
|
E.5.2 | Secondary end point(s) |
Progression Free Survival (PFS), Neurological Deterioration Free Survival (NDFS), best overall response distribution, objective and complete response, duration of objective or complete response |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
Objective or complete response rates, median OS, PFS, NDFS, objective or complete response duration. PFS6, PFS12, OS9, OS12, OS24, NDFS6, NDFS12 |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | Yes |
E.6.13.1 | Other scope of the trial description |
Translation research and Quality of Life |
|
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | Yes |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | Yes |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | Yes |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | No |
E.8.2.4 | Number of treatment arms in the trial | 2 |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 2 |
E.8.5 | The trial involves multiple Member States | Yes |
E.8.5.1 | Number of sites anticipated in the EEA | 32 |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | Yes |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.6.3 | If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned |
|
E.8.7 | Trial has a data monitoring committee | Yes |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
End of study occurs when all of the following criteria have been satisfied:
1. The trial is mature for the analysis of the primary endpoint (i.e. at least 1 year follow-up for each of the first 249 eligible patients).
2. The database has been fully cleaned and frozen for this analysis
3. Thirty days after all patients have stopped protocol treatment |
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 5 |
E.8.9.1 | In the Member State concerned months | 6 |
E.8.9.1 | In the Member State concerned days | 0 |
E.8.9.2 | In all countries concerned by the trial years | 5 |
E.8.9.2 | In all countries concerned by the trial months | 6 |
E.8.9.2 | In all countries concerned by the trial days | 0 |